Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., late Friday authorized a third, additional dose of the mRNA COVID-19 vaccines for people with moderately to severely compromised immune systems. This includes people who have:

  • been receiving active cancer treatment for tumors or cancers of the blood;
  • received an organ transplant and are taking medicine to suppress the immune system;
  • received a stem cell transplant within the last two years or are taking medicine to suppress the immune system;
  • moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome);
  • advanced or untreated HIV infection; and
  • are undergoing active treatment with high-dose corticosteroids or other drugs that may suppress your immune response.

CDC Tuesday, Aug. 17, at 2 p.m. ET will hold a call for clinicians to discuss additional doses, along with the current data on COVID-19 vaccines in immunocompromised people. Clinicians can follow this link to participate; a recording also will be available on the COCA Call webpage a few hours after the live event ends.

Related News Articles

Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…